Keiran S. M. Smalley

Department of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute

Affiliated withH. Lee Moffitt Cancer Center & Research Institute University of South Florida, H. Lee Moffitt Cancer Center & Research Institute

Research Area

Cancer Research

Biography

Keiran S. M. Smalley has not added Biography.
If you are Keiran S. M. Smalley and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

Article Total : 2	Year
Publication title	2021
Publication title	2024

Other Publications

Article	Year
XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation. The Journal of investigative dermatology\| PubMed ID: 26039542	2015
BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape. The Journal of investigative dermatology\| PubMed ID: 26302068	2015
Pharmacological research and precision cancer medicine: A call for manuscripts. Pharmacological research\| PubMed ID: 26542638	2015
Combination Therapies for Melanoma: A New Standard of Care? American journal of clinical dermatology\| PubMed ID: 26860106	2016
The role of phenotypic plasticity in the escape of cancer cells from targeted therapy. Biochemical pharmacology\| PubMed ID: 27349985	2016
Increased immunity and BRAF inhibition: Yet another argument for combination therapy? Pharmacological research\| PubMed ID: 27392741	2016
Ceritinib Enhances the Efficacy of Trametinib in -Wild-Type Melanoma Cell Lines. Molecular cancer therapeutics\| PubMed ID: 29133622	2018
The Blood Brain Barrier and BRAF inhibitors: Implications for patients with melanoma brain metastases. Pharmacological research\| PubMed ID: 29146209	2018
Get with the Program! Stemness and Reprogramming in Melanoma Metastasis. The Journal of investigative dermatology\| PubMed ID: 29273143	2018
The biology and therapeutic management of melanoma brain metastases. Biochemical pharmacology\| PubMed ID: 29278675	2018
ERK Inhibition: A New Front in the War against MAPK Pathway-Driven Cancers? Cancer discovery\| PubMed ID: 29431672	2018
Combined BRAF and HSP90 Inhibition in Patients with Unresectable -Mutant Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 29674508	2018
HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy. Cancer research\| PubMed ID: 30987999	2019
Pharmacological research and cancer: A call to arms. Pharmacological research\| PubMed ID: 31158465	2019
HDAC Inhibition Enhances the Efficacy of MEK Inhibitor Therapy in Uveal Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 31227503	2019
Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma. EBioMedicine\| PubMed ID: 31594749	2019
Translational pathology, genomics and the development of systemic therapies for acral melanoma. Seminars in cancer biology\| PubMed ID: 31689494	2020
Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 31924735	2020
Two Worlds Collide: Unraveling the Role of the Immune System in BRAF-MEK Inhibitor Responses. Cancer discovery\| PubMed ID: 32024680	2020
MEK-ing the most of it: strategies to co-target Gαq and MAPK in uveal melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 33355300	2020
Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity. Cancer immunology research\| PubMed ID: 33653716	2021
Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 34035069	2021
Ironing-Out the Details: New Strategies for Combining Ferroptosis Inhibitors with Immunotherapy in Melanoma. The Journal of investigative dermatology\| PubMed ID: 34565560	2022
HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma. Cancer gene therapy\| PubMed ID: 35332245	2022
Acral melanoma: new insights into the immune and genomic landscape. Neoplasia (New York, N.Y.)\| PubMed ID: 37913653	2023
HDAC8-mediated inhibition of EP300 drives a transcriptional state that increases melanoma brain metastasis. Nature communications\| PubMed ID: 38030596	2023
Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models. Journal for immunotherapy of cancer\| PubMed ID: 38056899	2023